Clinical Trials

Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Condition(s):

Eating Disorders
Bulimia nervosa
Binge-eating disorder
Bulimia
Eating Disorder
Obesity
Binge Eating Disorder

Purpose: This research study is designed to look at the effectiveness of bupropion for reducing binge eating in overweight persons with binge eating problems. Participants in the study will receive either bupropion or placebo ("sugar" pill, inactive medication) as an outpatient for eight weeks. In addition, participants will be given the option to receive 8 weeks of free behavioral weight loss treatment. This treatment, known to be effective for reducing binge eating and helping people lose weight, will be administered following the medication phase and at no cost. It is expected that compared to placebo, bupropion will produce greater reductions in binge eating.

Eligibility:

Minimum Age:

18 Years

Maximum Age:

65 Years

Accepts Healthy Volunteers:

No

Inclusion Criteria:

- BMI 25-50

- Able to travel to clinical site (New Haven, CT) for bi-weekly visits.

Exclusion Criteria:

- Predisposition to seizures

- History of anorexia or bulimia nervosa

- Current Type I or Type II diabetes mellitus

Other Location(s): New Haven, Connecticut United States

Terms: This is an abstract courtesy of ClinicalTrials.gov, a service of the US National Institute of Health Developed by the National Library of Medicine. ClinicalTrials.gov provides regularly updates information about federally and privately supported clinical research in human volunteers.